Impax Asset Management Group plc Purchases 8,240 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Impax Asset Management Group plc raised its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 1.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 766,761 shares of the company’s stock after buying an additional 8,240 shares during the quarter. Impax Asset Management Group plc’s holdings in SI-BONE were worth $10,750,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in SIBN. FMR LLC boosted its position in shares of SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after acquiring an additional 1,198 shares during the last quarter. R Squared Ltd bought a new position in SI-BONE during the fourth quarter valued at $73,000. Walleye Capital LLC purchased a new position in shares of SI-BONE in the 3rd quarter worth $144,000. Franklin Resources Inc. increased its holdings in shares of SI-BONE by 9.4% in the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock worth $265,000 after buying an additional 1,745 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of SI-BONE by 90.4% during the 3rd quarter. Janus Henderson Group PLC now owns 22,582 shares of the company’s stock valued at $316,000 after buying an additional 10,721 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Truist Financial boosted their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of SI-BONE in a research report on Monday, January 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.00.

Insider Activity

In other SI-BONE news, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now directly owns 222,814 shares of the company’s stock, valued at approximately $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the transaction, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is currently owned by company insiders.

SI-BONE Stock Down 2.1 %

Shares of SI-BONE stock opened at $17.47 on Tuesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a market cap of $732.66 million, a price-to-earnings ratio of -18.99 and a beta of 1.17. The firm’s 50-day moving average is $15.73 and its two-hundred day moving average is $14.69. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $20.60.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, research analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.